Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Daniel (cancer) Le (cancer)
Phone: 346.238.5655
Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are p ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator:
Phone:
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Daniel (cancer) Le (cancer)
Phone: 346.238.5655
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >